Prevalence of Germline Mutations in Polyposis and Colorectal Cancer–Associated Genes in Patients With Multiple Colorectal Polyps

• Published in: Clinical gastroenterology and hepatology Vol. 17; no. 10; pp. 2008 - 2015.e3
• Main Authors: Stanich, Peter P., Pearlman, Rachel, Hinton, Alice, Gutierrez, Stephanie, LaDuca, Holly, Hampel, Heather, Jasperson, Kory
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2019
• Subjects: Adenomatous Polyposis Coli; Gastroenterology and Hepatology; Genetic Analysis; Hereditary Neoplastic Syndromes; Prognostic Factor; Hereditary Neoplastic Syndromes; MGPT; NGS; Genetic Analysis; Adenomatous Polyposis Coli; Prognostic Factor; next-generation sequencing; multigene panel testing
• DOI: 10.1016/j.cgh.2018.12.008
• ISSN: 1542-3565; 1542-7714

Guidelines recommend genetic testing of patients with 10 or more cumulative adenomatous polyps. However, little is known about the utility of these tests—especially for older patients. We aimed to determine the prevalence of pathogenic mutations in patients with multiple colorectal polyps, stratified by age. We performed a cross-sectional study of patients with 10 or more colorectal polyps who underwent multigene panel testing (MGPT) from March 2012 through December 2016 (n = 3789). Demographic, clinical and family history data were obtained from test requisition forms and accompanying clinic notes, pedigrees, and pathology reports. Subjects were stratified based on reported polyp histology. Primary outcomes of interest were gene mutations associated with adenomatous polyposis, hamartomatous polyposis, and non-polyposis colorectal cancer syndromes. Based on MGPT, the prevalence of mutations in adenomatous polyposis genes decreased with increasing age in all polyp count groups in the adenoma cohort (P < .001 for 10–19, 20–99, and 100 or more polyps). The prevalence of mutations in all genes of interest also decreased with increasing age but remained above 5% in all age and polyp cohorts. Increased age at testing was associated with a significantly lower risk of a mutation in any gene of interest with multivariate analysis. In the hamartoma cohort, the prevalence of mutations in hamartomatous polyposis genes was high regardless of polyp count (40% with 10–19 polyps, 72.1% with 20–99 polyps, and 50% with 100 or more polyps). Our findings support continued genetic testing of patients with 10 or more polyps including adenomas and/or hamartomas. MGPT that includes analysis of polyposis and non-polyposis colorectal cancer genes should be considered for these patients given the high proportion with mutations (above 5%) in all age groups.